Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Novartis Announces 5-Year Results From Phase III NATALEE Trial Of Kisqali

Author: Benzinga Newsdesk | October 17, 2025 07:33am

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1
Data also show a 29.1% risk reduction in distant disease-free survival, and a positive trend in overall survival*1
- With a median of around two years post-completion of treatment with Kisqali, no new safety signals were observed

Posted In: NVS